P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial primary completion date: Jun 2026 --> Jun 2028

P4, N=440, Completed, Ministry of Health

P1, N=30, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University

P2, N=130, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Canc

P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P1, N=24, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended

These results suggest that amodiaquine derivatives have anti-COAD actions due to their disruption of important immune-regulatory and apoptotic pathways. These findings computationally prioritize amodiaquine and desethylamodiaquine as candidate multi-target interactors in colon adenocarcinoma, warranting further experimental investigation rather than implying established therapeutic efficacy.

P1, N=24, Not yet recruiting, University of Oxford

P1, N=8, Recruiting, Janssen Cilag International

P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028

P4, N=380, Recruiting, Yale University | Not yet recruiting --> Recruiting

Using Aadac knockout (KO) mice, we demonstrated that CCl4, APAP, and amodiaquine induced more severe liver damage in the absence of Aadac, with elevated ferrous (Fe2+) levels, lipid peroxidation, and oxidative stress...Furthermore, human AADAC overexpression in Huh-7 cells similarly reduced intracellular Fe2+ levels and conferred protection against CCl4-induced cytotoxicity in a ceruloplasmin-dependent manner. These findings reveal a novel, non-catalytic role for AADAC in iron homeostasis and ferroptosis suppression, suggesting its clinical significance in DILI susceptibility and therapy.